Gerresheimer AG (SWX:GXI)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 838.01M -56.3% |
| Revenue (ttm) | 2.11B +11.8% |
| Net Income | 21.85M -79.6% |
| EPS | 0.63 -79.6% |
| Shares Out | n/a |
| PE Ratio | 38.35 |
| Forward PE | 9.64 |
| Dividend | 0.04 (0.15%) |
| Ex-Dividend Date | Jun 6, 2025 |
| Volume | n/a |
| Average Volume | 168 |
| Open | 24.74 |
| Previous Close | 24.74 |
| Day's Range | 24.74 - 24.74 |
| 52-Week Range | 16.16 - 24.76 |
| Beta | n/a |
| RSI | 74.66 |
| Earnings Date | Apr 16, 2026 |
About Gerresheimer AG
Gerresheimer AG, together with its subsidiaries, provides medicine packaging, drug delivery devices, and solutions in Germany and internationally. The company operates through three divisions: Plastics & Devices, Primary Packaging Glass, and Advanced Technologies. It offers prefillable syringes, plastic and glass packaging solutions, vials, glass cartridges and ampoules, bottles and containers, and containers, bottles, caps, closures, applicators, and accessories; development, industrialization and contract manufacturing of drug delivery progra... [Read more]
Financial Performance
In fiscal year 2024, Gerresheimer AG's revenue was 2.04 billion, an increase of 2.28% compared to the previous year's 1.99 billion. Earnings were 109.72 million, a decrease of -5.52%.
Financial numbers in EUR Financial StatementsNews
EQS-PVR: Gerresheimer AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Voting Rights Announcement: Gerresheimer AG Gerresheimer AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distributi...
EQS-DD: Gerresheimer AG: AOC Gecko S.à r.l., buy
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 07.05.2026 / 17:10 CET/CEST The issuer is solely responsi...
EQS-DD: Gerresheimer AG: Active Ownership Fund SICAV SIF SCS, buy
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 07.05.2026 / 17:08 CET/CEST The issuer is solely responsi...
EQS-DD: Gerresheimer AG: Active Ownership Fund SICAV SIF SCS, Kauf
Gerresheimer downgraded to Underweight from Equal Weight at Barclays
Barclays downgraded Gerresheimer (GRRMF) to Underweight from Equal Weight with a price target of EUR 19, down from EUR 23. The firm prefers device manufacturing to drug containment solutions in
Gerresheimer rejects takeover bid from Silgan, Reuters reports
Gerresheimer (GRRMF) has rejected a takeover bid from Silgan (SLGN) and there are no longer any discussions between the two companies, Reuters reports, citing three sources familiar with the situation...
Gerresheimer rejects takeover bid from US packing firm Silgan, say sources
German medical packaging maker Gerresheimer has rejected a takeover bid from its U.S. rival Silgan , three sources familiar with the situation told Reuters.
EQS-Adhoc: Gerresheimer AG: Creditors agree to extend the due date for submitting the audited 2025 annual and consolidated financial statements
EQS-Ad-hoc: Gerresheimer AG / Key word(s): Significant contracts Gerresheimer AG: Creditors agree to extend the due date for submitting the audited 2025 annual and consolidated financial statements 15...
Gerresheimer delays 2025 results release to June, stock to be removed from SDAX
Gerresheimer on Tuesday again deferred the release of 2025 financial statements to June, citing a probe into its business deals, a delay that is now set to cost the German medical products maker ...
Gerresheimer downgraded to Sell from Neutral at UBS
UBS downgraded Gerresheimer (GRRMF) to Sell from Neutral with a price target of EUR 12.90, down from EUR 29. The firm is cutting estimates for the short- and mid-term to
Gerresheimer downgraded to Underperform from Neutral at BNPP
BNPP downgraded Gerresheimer (GRRMF) to Underperform from Neutral with a EUR 22 price target
Gerresheimer price target lowered to EUR 30 from EUR 55 at Berenberg
Berenberg analyst Christian Ehmann lowered the firm’s price target on Gerresheimer (GRRMF) to EUR 30 from EUR 55 and keeps a Hold rating on the shares.
Gerresheimer appoints Uwe Röhrhoff as new interim CEO
Medical equipment maker Gerresheimer said on Tuesday it had appointed Uwe Röhrhoff as interim CEO, effective November 1, 2025. He succeeds Dietmar Siemssen, who will step down as CEO by mutual agreeme...
Gerresheimer finds 2024 revenue-recognition issues after external probe
Medical equipment maker Gerresheimer said it has obtained the initial findings from an investigation by an external law firm into the recognition of revenue and profit from bill-and-hold agreements in...
Gerresheimer downgraded to Equal Weight from Overweight at Barclays
Barclays downgraded Gerresheimer (GRRMF) to Equal Weight from Overweight with a price target of EUR 23, down from EUR 64. The firm says visibility into the investment case is low
Gerresheimer price target lowered to EUR 46 from EUR 99.30 at JPMorgan
JPMorgan lowered the firm’s price target on Gerresheimer (GRRMF) to EUR 46 from EUR 99.30 and keeps an Overweight rating on the shares.
Gerresheimer downgraded to Neutral from Buy at UBS
UBS analyst Olivier Calvet downgraded Gerresheimer (GRRMF) to Neutral from Buy with a price target of EUR 29, down from EUR 75. The firm sees uncertainties following the company’s third
Gerresheimer price target lowered to EUR 34 from EUR 49 at Deutsche Bank
Deutsche Bank analyst Falko Friedrichs lowered the firm’s price target on Gerresheimer (GRRMF) to EUR 34 from EUR 49 and keeps a Hold rating on the shares. Published first on
Gerresheimer downgraded to Sell from Hold at DZ Bank
DZ Bank downgraded Gerresheimer (GRRMF) to Sell from Hold with a EUR 25 price target
Gerresheimer AG Earnings Call Transcript: Q3 2025
Q3 and nine-month results were below expectations, with organic revenue and EBITDA declines driven by weak cosmetics and oral liquids markets. Guidance was revised downward, a transformation program was launched, and liquidity remains strong with no covenant breaches.
Gerresheimer's shares fall 11% after another outlook cut
Shares in Gerresheimer fell 11% on Thursday, a day after the German packaging and medical equipment maker cut its 2025 guidance for the third time this year.
Gerresheimer AG Earnings Call Transcript: Q3 2025
Q3 and the first nine months of 2025 were below expectations, with organic revenue and EBITDA both declining year-over-year. Guidance was revised downward, with a projected organic revenue decline of -4% to -2% and an adjusted EBITDA margin of 18.5%-19%.
Gerresheimer cuts 2025 outlook again as Q3 disappoints
German packaging and medical equipment maker Gerresheimer cut its 2025 guidance again on Wednesday, now expecting organic revenues to decline between 2-4% as third quarter results fell below expectati...
Gerresheimer shares tank as financial regulator suspects accounting flaws
Shares in medical equipment maker Gerresheimer plunged as much as 38% on Wednesday after Germany's financial regulator said it was investigating suspected accounting rule violations.
Gerresheimer CFO resigns unexpectedly, successor to take over from September
Gerresheimer Chief Financial Officer Bernd Metzner has resigned from his role and will leave the company on August 31, the German packaging and medical equipment maker said on Friday.